/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Delaware Enhanced Global Dividend and Income Fund Announces Self-Tender Offer for up to Five Percent of Its Shares
PHILADELPHIA–(BUSINESS WIRE)–Delaware Enhanced Global Dividend and Income Fund (NYSE: DEX) (the
“Fund”) announced today that its Board of Trustees has authorized an
issuer tender offer to purchase for cash up to 631,965 of its common
shares, representing five percent of its issued and outstanding common
shares, without par value. The tender offer will commence on Friday, May
31, 2019, and will expire, unless extended, at 11:59 p.m., New York City
time, on Thursday, June 27, 2019. Subject to various terms and
conditions described in offering materials to be distributed to
shareholders: (1) purchases will be made at a price per share equal to
98% of the Fund’s net asset value per share as of the close of trading
on the first business day after the expiration of the offer; and (2) if
more shares are tendered than the amount the Board has authorized to
purchase, the Fund will purchase a number of shares equal to the offer
amount on a prorated basis.
The Fund’s common shares have recently traded at a discount to their net
asset value per share. During the pendency of the tender offer, the
current net asset value per share will be available by telephone at 888
605-8334 or on the Fund’s website at delawarefunds.com/closed-end.
The Fund’s primary investment objective is to seek current income, with
a secondary objective of capital appreciation. The Fund invests globally
in dividend-paying or income-generating securities across multiple asset
classes, including but not limited to: equity securities of large,
well-established companies; securities issued by real estate companies
(including real estate investment trusts and real estate industry
operating companies); debt securities (such as government bonds;
investment grade and high risk, high yield corporate bonds; and
convertible bonds); and emerging market securities. The Fund also uses
enhanced income strategies by engaging in dividend capture trading;
option overwriting; and realization of gains on the sale of securities,
dividend growth, and currency forwards. There is no assurance that the
Fund will achieve its investment objectives.
Under normal market conditions, the Fund will invest: (1) at most 60% of
its net assets in securities of U.S. issuers; and (2) at least 40% of
its net assets in securities of non-U.S. issuers, unless market
conditions are not deemed favorable by the Manager, in which case, the
Fund would invest at least 30% of its net assets in securities of
non-U.S. issuers; and (3) the Fund may invest up to 25% of its net
assets in securities issued by real estate companies (including real
estate investment trusts and real estate industry operating companies).
In addition, the Fund utilizes leveraging techniques in an attempt to
obtain higher return for the Fund.
The Fund has implemented a managed distribution policy. Under the
policy, the Fund is managed with a goal of generating as much of the
distribution as possible from net investment income and short-term
capital gains. The balance of the distribution will then come from
long-term capital gains to the extent permitted, and if necessary, a
return of capital. A return of capital may occur for example, when some
or all of the money that you invested in the Fund is paid back to you. A
return of capital distribution does not necessarily reflect the Fund’s
investment performance and should not be confused with ‘yield’ or
‘income’. Even though the Fund may realize current year capital gains,
such gains may be offset, in whole or in part, by the Fund’s capital
loss carryovers from prior years.
Currently under the Fund’s managed distribution policy, the Fund makes
monthly distributions to common shareholders at a targeted annual
distribution rate of 10% of the Fund’s average net asset value (“NAV”)
per share. The Fund will calculate the average NAV per share from the
previous three full months immediately prior to the distribution based
on the number of business days in those three months on which the NAV is
calculated. The distribution will be calculated as 10% of the prior
three month’s average NAV per share, divided by 12. The Fund will
generally distribute amounts necessary to satisfy the Fund’s managed
distribution policy and the requirements prescribed by excise tax rules
and Subchapter M of the Internal Revenue Code. This distribution
methodology is intended to provide shareholders with a consistent, but
not guaranteed, income stream and a targeted annual distribution rate
and is intended to narrow any discount between the market price and the
NAV of the Fund’s common shares, but there is no assurance that the
policy will be successful in doing so. The methodology for determining
monthly distributions under the Fund’s managed distribution policy will
be reviewed at least annually by the Fund’s Board of Trustees, and the
Fund will continue to evaluate its distribution in light of ongoing
market conditions.
Shareholders are advised to read the offer to purchase when it is
available, as it contains important information.
The offer to purchase and other documents filed by the Fund with the
U.S. Securities and Exchange Commission (SEC), including the Fund’s
annual report for the fiscal year ended November 30, 2018, are or will
be available without cost at the Commission’s website (sec.gov)
or by calling the Fund’s Information Agent.
About Macquarie Investment Management
Macquarie Investment Management, a member of Macquarie Group, includes
the former Delaware Investments and is a global asset manager with
offices throughout the United States, Europe, Asia, and Australia. As
active managers, we prioritize autonomy and accountability at the team
level in pursuit of opportunities that matter for clients. Macquarie
Investment Management is supported by the resources of Macquarie Group
(ASX: MQG; ADR: MQBKY), a global provider of asset management,
investment, banking, financial and advisory services.
Advisory services are provided by Macquarie Investment Management
Business Trust, a registered investment advisor. Macquarie Group refers
to Macquarie Group Limited and its subsidiaries and affiliates
worldwide. For more information about Delaware Funds® by
Macquarie, visit delawarefunds.com or call 800 523-1918.
Other than Macquarie Bank Limited (MBL), none of the entities referred
to in this document are authorized deposit-taking institutions for the
purposes of the Banking Act 1959 (Commonwealth of Australia). The
obligations of these entities do not represent deposits or other
liabilities of MBL, a subsidiary of Macquarie Group Limited and an
affiliate of Macquarie Investment Management. MBL does not guarantee or
otherwise provide assurance in respect of the obligations of these
entities, unless noted otherwise.
© 2019 Macquarie Management Holdings, Inc.
Contacts
Investors
Georgeson LLC (during pendency of the tender offer)
888
605-8334
delawarefunds.com/closed-end
Media contacts
Daniela Palmieri
215 255-8878
Jessica Fitzgerald
215 255-1336
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Humboldt
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
Apollo Green to distribute Humboldt Seed Company clonal cannabis genetics to Germany, Portugal and Australia
SAN FRANCISCO, April 30, 2024 /PRNewswire/ — Humboldt Seed Company (HSC), California’s leading cannabis seed producer, has announced a partnership with Canadian-based Apollo Green to make eight breeder cuts available to researchers, licensed commercial cultivators and home growers in legal markets worldwide. This first-to-market clonal genetics release is a significant milestone and will expand access to distinctive, high-quality cannabis genetics in both established and emerging global markets including Germany, Portugal and Australia.
The curated, breeder-verified selection includes pioneering triploid genetics, such as OG Triploid and Donutz Triploid alongside the legendary cult classic Blueberry Muffin. Also available are All Gas OG with a THC content of 21% and four high-THC strains in the 30-35% range: Golden Sands, Guzzlerz, Jelly Donutz and Orange Creampop. These selections represent the top .01% from HSC’s extensive California pheno-hunting program.
Exports will begin in May under Apollo Green’s Canadian federal cannabis license. All shipments have Canadian phytosanitary certification, ensuring plants have been inspected, and are clean and free of pests.
“Access for all to quality genetics has been our core focus since the beginning,” said HSC Co-founder and Chief Science Officer, Benjamin Lind. “Our science-based approach to breeding aligns perfectly with Apollo Green’s high standards and we are excited to be able to extend these hand-selected cuts to a wider audience, especially at this pivotal time where we’re seeing positive regulatory changes globally.”
Oisin Tierney, Apollo Green Director of Business Development, said, “California has long been recognized for setting industry standards, and we are proud to play a role in bringing these esteemed genetics to cultivators worldwide. The triploids are especially noteworthy in terms of the unprecedented potential for enhanced plant vigor, higher yields, shorter flowering times and superior returns for solventless extraction.”
About Humboldt Seed Company
Established in 2001, Humboldt Seed Company is a Northern California heritage brand providing quality cannabis genetics to commercial cultivators and home growers in legalized states across the U.S. and international markets including Spain, Canada, Jamaica, South Africa, Colombia, France, Portugal, Greece, the UK, Malta and Thailand. With a focus on environmental and social justice, they combine traditional breeding and modern scientific practices in their strain development program. They have served the cannabis community for over two decades.
For more information visit https://humboldtseedcompany.com/.
About Apollo Green
Licensed since 2019, Apollo Green is Canada’s leader in cannabis genetics. The company’s mission is to provide an ever-growing bank of seeds and clones to medical patients and recreational consumers. Apollo Green provides clean, trusted cannabis seeds and clones, which are backed by the foremost tissue culture technology to reduce risks, costs and time-to-market for licensed producers around the world. Apollo Green is passionate about cannabis genetics.
For more information visit https://apollogreen.com/.
Media contact
Jaana Prall
[email protected]
Logo – https://mma.prnewswire.com/media/2328955/Humboldt_Seed_Company_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/humboldt-seed-company-partners-with-apollo-green-to-bring-california-cannabis-genetics-to-the-global-marketplace-302131618.html
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan2 weeks ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf2 weeks ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
SCHWAZZE4 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis3 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt3 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace